ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1213

Using Patient-Reported Disease Activity in a Population-Based Cohort to Predict Systemic Lupus Erythematous Hospitalization and Emergency Room Visits

S. Sam Lim1, Sandra Wu2, Ryan Ross3, Gaobin Bao1, Megan Richards3, Liisa Palmer3 and Gary Bryant4, 1Emory University, Atlanta, GA, 2AstraZeneca, Hockessin, DE, 3Merative, Cambridge, MA, 4AstraZeneca, New Castle, DE

Meeting: ACR Convergence 2023

Keywords: Patient reported outcomes, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1200–1220) Patient Outcomes, Preferences, & Attitudes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that has a large range of clinical manifestations, some of which can be severe. Reducing SLE flares leading to emergency room (ER) visits and hospitalizations is often difficult for clinicians given the heterogeneity of symptoms that can identify at-risk patients. The SLE Activity Questionnaire (SLAQ), a validated patient-reported instrument designed to screen disease activities in the clinical settings, may be a novel way to predict SLE-related healthcare utilization; but such association and application has not been studied and there have been few data to support its use in the clinical setting. The purpose of this analysis was to assess the patient-reported disease activity symptoms using SLAQ components in a population-based lupus cohort and develop a predictive model to identify patients at a higher risk for SLE-related hospitalization and ER visits.

Methods: This study used data from two surveys (2011-2013) of the Georgians Organized Against Lupus (GOAL) cohort, a Centers for Disease Control and Prevention supported population-based cohort of validated SLE patients in Atlanta who complete annual surveys, including sociodemographic and the SLAQ. This database was linked with the Georgia Hospital Discharge Database to obtain ER visits and hospitalizations within 6 months of each survey. An SLE-related hospitalization or ER visit is defined based on diagnosis of SLE-related condition in the primary position within 6 months of GOAL survey completion. The unadjusted association between SLAQ components and SLE-hospitalizations or ER visits was assessed using logistic regression to identify the strongest SLAQ predictors. A classification and regression tree (CART) model generated a decision tree for predicting SLE-hospitalization or ER risk based on the SLAQ components.

Results: Of the 1,486 GOAL participants, 136 (9.2%) had an SLE-related hospitalization or ER visit within 6-months of survey completion. The mean age at survey completion was 47 (SD: 13) years, 94% of patients were female, 78% of patients were Black, and had SLE for 14 (9) years. Patients with ≥1 SLE-related hospitalizations or ER visits had higher SLAQ scores than those without hospitalization (22 vs. 17; Table 1). The risk of SLE-related hospitalization or ER visit was higher among patients with higher disease activity scores, chest pain with deep breath, and those with more SLE flares (Figure 1). CART modeling suggests patients who had chest pain with deep breath and fevers as the high-risk group with 18.8% likelihood of an SLE-related hospitalization or ER visit in the next 6 months. The high-risk group have a 2-fold increased risk than the average patients (Pr=9.2%), and a 4-to-6-fold risk than those identified as low-risk (Pr=3.2-4.5%).

Conclusion: Patients who reported chest pain with deep breath and fevers were at the highest risk of having anSLE-related hospitalization or ER visit within 6 months. The inclusion of the SLAQ in routine care may provide physicians and patients with valuable information that could help mitigate healthcare utilization and improve outcomes.

Supporting image 1

Supporting image 2


Disclosures: S. Lim: None; S. Wu: AstraZeneca, 3; R. Ross: None; G. Bao: None; M. Richards: None; L. Palmer: None; G. Bryant: AstraZeneca, 3.

To cite this abstract in AMA style:

Lim S, Wu S, Ross R, Bao G, Richards M, Palmer L, Bryant G. Using Patient-Reported Disease Activity in a Population-Based Cohort to Predict Systemic Lupus Erythematous Hospitalization and Emergency Room Visits [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/using-patient-reported-disease-activity-in-a-population-based-cohort-to-predict-systemic-lupus-erythematous-hospitalization-and-emergency-room-visits/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/using-patient-reported-disease-activity-in-a-population-based-cohort-to-predict-systemic-lupus-erythematous-hospitalization-and-emergency-room-visits/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology